Lobbying Information
Subject Matters
- Budget
- Health
- Industry
- Intellectual Property
- International Development
- International Trade
- Justice and Law Enforcement
- Privacy and Access to Information
- Research and Development
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
- Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
- Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Research and Development: Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D
Policies or Program
- Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
- Input into the Patented Medicines Price Review Board evaluation of annual Research and Development investments by companies in Canada based on SR&ED tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
- National Pharmacare. Specifically the proposed delivery of a universal pharmacare program. This universal format would eliminate the private insurance benefit industry and thereby reducing the amount of medications available to Canadians
Policies or Program, Regulation
- Health Canada PMPRB proposed regulation changes are the regulatiuons
Health Canada consulted on Proposed Amendments to the Patented Medicines Regulations. Discussions on changing the basket of comparative countries and its unintended economic consequences in Canada. In particular its impact on the Life Sciences Sector and wait times for medicines for Canadians
Title: “Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations”
Regulation
- An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
- Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (EMA/FDA).
- Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Research based bio-pharmaceutical company
Resarch and development, sales and marketing of innovative drugs
Responsible officer name and position during the period of this registration
Jorge Bartolome,
President
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
19 Green Belt Drive
Toronto, ON M3C 1L9
Canada
Telephone number:
416-382-5082
Parent Company Information
- Johnson & Johnson
-
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States of America
Subsidiary Beneficiary Information
Janssen Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Derek Badger,
Manager, Government Affairs |
No public offices held
- Jorge Bartolome,
President |
No public offices held
- David Cotes,
Manager Government Affairs |
No public offices held
- Paul de Zara,
Director Patient Access & Government Affairs |
No public offices held
- Brenda Fisher,
Manager, Government Affairs & Market Access |
No public offices held
- Alaine Grand,
VP Government Affairs & Market Access |
No public offices held
- Cathy Lau,
VP Regulatory Affairs |
No public offices held
- Colin Le Fevre,
Manager, Policy |
No public offices held
- Carole Watson,
National Director, Government Affairs & Market Access |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Lesia Babiak,
Director |
No public offices held
- Jacqueline Dobson,
Mgr Government Relations (ON) |
No public offices held
- Peter Dyrda,
Strategic Access Mgr. Ontario |
No public offices held
